Abstract
Objective To observe the clinical effectiveness and safety of general surgical treatment of end-stage liver disease. Methods One hundred and two patients with end-stage liver disease were selected, patients underwent stem cell transplantation were assigned to group A (67 cases), patients didn’t underwent stem cell transplantation were assigned to group B (35 cases). In 2, 4, 8, 12, 24 weeks after treatment, followed up and recorded changes of serum ALB, PTA, CHE, TBil and the clinical symptom scores and other indicators. The prognosis and complications were compared between the two groups, the effect and safety of the operation was evaluated. Results Followed up for 2, 4, 8, 12 and 24 weeks, the changes of serum TBil had no statistical significance (P>0.05); Followed up for 2 weeks, the changes of serum ALB, PTA, CHE between the two groups had no statistical significance (P>0.05); Followed up for 4, 8, 12 and 24 weeks, the changes of serum ALB, PTA, CHE between the two groups had statistical significance differences (P 0.05). Conclusions General surgical treatment in patients with end-stage liver disease can significantly improve the serum level of ALB, PTA, CHE, and improve the clinical symptoms of patients. Key words: End-stage liver disease; Autologous bone marrow; Stem cell transplantation; Curative effect; Safety
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
